Literature DB >> 9438653

Efficacy of taxol in the orpk mouse model of polycystic kidney disease.

C S Sommardahl1, R P Woychik, W E Sweeney, E D Avner, J E Wilkinson.   

Abstract

Polycystic kidney disease (PKD) a is common disease in the human population that can lead to renal failure and death. Taxol has recently been reported to be of therapeutic benefit in the cpk mouse model of PKD. To determine whether these results also apply to other models of PKD, we studied the effects of taxol treatment on the development of renal cysts and biliary hyperplasia/dysplasia/fibrosis in the orpk mouse mutant, a unique murine model for human autosomal recessive PKD. We report no significant differences between the treatment and control groups with respect to weight gain, survival, urine to serum osmolality ratio, and serum concentration of liver enzymes. Moreover, renal cystic development was not affected by taxol treatment in the orpk mutant animals. This was confirmed by lectin staining and morphometric analysis of the renal cysts, which indicated no significant differences between treatment groups. Therefore, while taxol has a positive effect on the cystic kidney disease in cpk mutant mice, this effect is not applicable to all forms of PKD.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9438653     DOI: 10.1007/s004670050376

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  8 in total

Review 1.  Diagnosis, pathogenesis, and treatment prospects in cystic kidney disease.

Authors:  Carsten Bergmann; Valeska Frank; Fabian Küpper; Dirk Kamitz; Jens Hanten; Peter Berges; Silke Mager; Markus Moser; Jutta Kirfel; Reinhard Büttner; Jan Senderek; Klaus Zerres
Journal:  Mol Diagn Ther       Date:  2006       Impact factor: 4.074

2.  Galectin-3 associates with the primary cilium and modulates cyst growth in congenital polycystic kidney disease.

Authors:  Miliyun G Chiu; Tanya M Johnson; Adrian S Woolf; Eugenia M Dahm-Vicker; David A Long; Lisa Guay-Woodford; Katherine A Hillman; Suleman Bawumia; Kerrie Venner; R Colin Hughes; Francoise Poirier; Paul J D Winyard
Journal:  Am J Pathol       Date:  2006-12       Impact factor: 4.307

Review 3.  Drug discovery for polycystic kidney disease.

Authors:  Ying Sun; Hong Zhou; Bao-xue Yang
Journal:  Acta Pharmacol Sin       Date:  2011-06       Impact factor: 6.150

4.  Cystin, a novel cilia-associated protein, is disrupted in the cpk mouse model of polycystic kidney disease.

Authors:  Xiaoying Hou; Michal Mrug; Bradley K Yoder; Elliot J Lefkowitz; Gabriel Kremmidiotis; Peter D'Eustachio; David R Beier; Lisa M Guay-Woodford
Journal:  J Clin Invest       Date:  2002-02       Impact factor: 14.808

Review 5.  Recent advances in understanding the pathogenesis of polycystic kidney disease: therapeutic implications.

Authors:  Benjamin D Cowley
Journal:  Drugs       Date:  2004       Impact factor: 9.546

Review 6.  Nephronophthisis: should we target cysts or fibrosis?

Authors:  Gisela G Slaats; Marc R Lilien; Rachel H Giles
Journal:  Pediatr Nephrol       Date:  2015-07-29       Impact factor: 3.714

7.  Gene therapy rescues cilia defects and restores olfactory function in a mammalian ciliopathy model.

Authors:  Jeremy C McIntyre; Erica E Davis; Ariell Joiner; Corey L Williams; I-Chun Tsai; Paul M Jenkins; Dyke P McEwen; Lian Zhang; John Escobado; Sophie Thomas; Katarzyna Szymanska; Colin A Johnson; Philip L Beales; Eric D Green; James C Mullikin; Aniko Sabo; Donna M Muzny; Richard A Gibbs; Tania Attié-Bitach; Bradley K Yoder; Randall R Reed; Nicholas Katsanis; Jeffrey R Martens
Journal:  Nat Med       Date:  2012-09       Impact factor: 53.440

8.  Taxol and taurine protect the renal tissue of rats after unilateral ureteral obstruction: a stereological survey.

Authors:  Saied Karbalay-Doust; Ali Noorafshan; Seyed-Mohammad Pourshahid
Journal:  Korean J Urol       Date:  2012-05-18
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.